Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 28-12-2015
AUM:
₹ 1,511.49 Cr
Expense Ratio
2.37%
Benchmark
NIFTY Pharma TRI
ISIN
INF277K016A9
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Rajat Srivastava
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | 1.05 | 16.73 | 12.47 |
| Nifty Pharma TRI | 18.44 | 22.05 | 14.09 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
31.1636
Last change
0.57 (1.8284%)
Fund Size (AUM)
₹ 1,511.49 Cr
Performance
11.02% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund Manager
Rajat Srivastava
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 7.99 |
| ABBOTT INDIA LIMITED EQ | 5.94 |
| HEALTHCARE GLOBAL ENTERPRISES LTD EQ | 5.92 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 5.68 |
| Dr. Reddys Laboratories Ltd | 4.65 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 4.36 |
| RAINBOW CHILDRENS MEDICARE LIMITED EQ | 4.3 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 4.22 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 3.76 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 3.71 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 88.97 |
| Chemicals | 9.52 |
| Fast Moving Consumer Goods | 1.23 |
Peer Comparison
| Scheme Name | 5Y (%) |
|---|---|
| Tata India Pharma & Healthcare Reg Gr | 12.47 |